SCHEMBL1551092

SCHEMBL1551092

O=C(O)COc1ccc(C#Cc2ccc(CO)cc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 6/20 0.72
ALOX15 P16050 1/20 0.53
PRKAG1 P54619 1/20 0.51
PRKAA1 Q13131 1/20 0.51
PRKAB1 Q9Y478 1/20 0.51
ALDH1A1 P00352 2/20 0.50
EGLN1 Q9GZT9 1/20 0.49
NR4A1 P22736 1/20 0.49
APEX1 P27695 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 1/20 0.47
PTPN7 P35236 1/20 0.47
PTPN12 Q05209 1/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.46
TBXAS1 P24557 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL166364 0.91 ALOX15 (0.63) FFAR1ALOX15ALDH1A1NR4A1APEX1
SCHEMBL12646485 0.86 ALOX15 (0.57) FFAR1ALOX15ALDH1A1NR4A1APEX1
SCHEMBL1551003 0.84 FFAR1 (1.00) FFAR1ALOX15ALDH1A1SMN1; SMN2MEN1
SCHEMBL1550206 0.82 FFAR1 (0.77) FFAR1ALOX15ALDH1A1SMN1; SMN2MEN1
SCHEMBL1550667 0.81 FFAR1 (0.74) FFAR1ALOX15ALDH1A1NR4A1APEX1
SCHEMBL1551617 0.80 GAA (0.56) FFAR1ALDH1A1SMN1; SMN2MAPTTBXAS1
SCHEMBL339492 0.79 ALOX15 (0.81) FFAR1ALOX15ALDH1A1NR4A1APEX1
SCHEMBL16624600 0.77 TSHR (0.48) FFAR1EGLN1
SCHEMBL2439826 0.77 ALOX15 (0.59) FFAR1ALOX15ALDH1A1SMN1; SMN2MEN1
SCHEMBL4883406 0.76 PTPN7 (0.67) FFAR1ALOX15ALDH1A1NR4A1APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586607-B2 Compounds for the treatment of metabolic diseases SYDDANSK UNIVERSITET (DK) 2013-11-19 US disclosed
US-8586607-B2 Compounds for the treatment of metabolic diseases SYDDANSK UNIVERSITET (DK) 2013-11-19 US disclosed
EP-2313360-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES UNIV SYDDANSK (DK) 2012-09-05 EP disclosed
EP-2313360-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES UNIV SYDDANSK (DK) 2012-09-05 EP disclosed
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET 2011-06-23 US disclosed
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET 2011-06-23 US disclosed
EP-2313360-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES Syddansk Universitet (DK) 2011-04-27 EP disclosed
WO-2010012650-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET (DK) 2010-02-04 WO disclosed
WO-2010012650-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET (DK) 2010-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES GPR119, INSR, GPR65 FFAR1 6/4885ALOX15 763/4885PRKAG1 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.